SoftOx Solutions AS (SoftOx), a clinical-stage biopharmaceutical company based
in Norway, announced today the end of the Phase 1 clinical study of the SoftOx
Biofilm Eradicator (SBE-01) (EudraCT no. 2021-000314-42), SoftOx's antimicrobial
solution for treatment of chronic wounds.

"We would like to thank our study participants and the staff at DanTrials ApS.
SoftOx is looking forward to announcing the top line results in Q4 2022," said
Glenn Gundersen, Sr Medical Director of SoftOx. 

SBE-01 is a first-in-human study investigating the safety, tolerability, and
antimicrobial efficacy of single and multiple doses of the SoftOx Biofilm
Eradicator (SBE) in patients with venous leg ulcers. In Phase 1b the company
treated the wounds once and twice daily over 5 days. The original study design
included three times daily administration for five days